These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26761214)

  • 1. Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells.
    Daniele S; Barresi E; Zappelli E; Marinelli L; Novellino E; Da Settimo F; Taliani S; Trincavelli ML; Martini C
    Oncotarget; 2016 Feb; 7(7):7866-84. PubMed ID: 26761214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma.
    Daniele S; Taliani S; Da Pozzo E; Giacomelli C; Costa B; Trincavelli ML; Rossi L; La Pietra V; Barresi E; Carotenuto A; Limatola A; Lamberti A; Marinelli L; Novellino E; Da Settimo F; Martini C
    Sci Rep; 2014 Apr; 4():4749. PubMed ID: 24756113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas.
    Daniele S; La Pietra V; Barresi E; Di Maro S; Da Pozzo E; Robello M; La Motta C; Cosconati S; Taliani S; Marinelli L; Novellino E; Martini C; Da Settimo F
    J Med Chem; 2016 May; 59(10):4526-38. PubMed ID: 27050782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
    Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long lasting inhibition of Mdm2-p53 interaction potentiates mesenchymal stem cell differentiation into osteoblasts.
    Daniele S; Giacomelli C; Pietrobono D; Barresi E; Piccarducci R; La Pietra V; Taliani S; Da Settimo F; Marinelli L; Novellino E; Martini C; Trincavelli ML
    Biochim Biophys Acta Mol Cell Res; 2019 May; 1866(5):737-749. PubMed ID: 30703414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
    Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
    Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
    Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
    Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
    Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
    Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
    Wang Z; Song T; Feng Y; Guo Z; Fan Y; Xu W; Liu L; Wang A; Zhang Z
    J Med Chem; 2016 Apr; 59(7):3152-62. PubMed ID: 26982372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
    Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
    Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
    Song Y; Zhang L; Jiang Y; Hu T; Zhang D; Qiao Q; Wang R; Wang M; Han S
    Theranostics; 2019; 9(20):6019-6030. PubMed ID: 31534534
    [No Abstract]   [Full Text] [Related]  

  • 15. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
    Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
    Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance.
    Costa B; Da Pozzo E; Giacomelli C; Taliani S; Bendinelli S; Barresi E; Da Settimo F; Martini C
    Apoptosis; 2015 Mar; 20(3):383-98. PubMed ID: 25413799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitin-specific protease 2a stabilizes MDM4 and facilitates the p53-mediated intrinsic apoptotic pathway in glioblastoma.
    Wang CL; Wang JY; Liu ZY; Ma XM; Wang XW; Jin H; Zhang XP; Fu D; Hou LJ; Lu YC
    Carcinogenesis; 2014 Jul; 35(7):1500-9. PubMed ID: 24445145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide.
    Zheng M; Yang J; Xu X; Sebolt JT; Wang S; Sun Y
    Anticancer Res; 2010 Sep; 30(9):3321-31. PubMed ID: 20944104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
    Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
    Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.